RxDoctor Payments Data

Ammar Safar, MD

Cardiovascular Disease · Miamisburg, OHNPI 1558334581

Payments from drug & device makers

$106,330in general payments, 2019–2025

Across 104 payments — averaging $1022.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$50K
  • Angiodynamics, Inc.$45K
  • Medtronic$5K
  • Penumbra, Inc.$3K
  • Abiomed$671
  • Abbott$619
  • plus $1K from 12 others

What the payments were for

  • Travel & lodging$3,84046%
  • Food & beverage$4,56954%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,330 in reported general payments places this provider in the 90th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$192,852
Medicare patients
682
Services billed
1,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban860$750,151
EntrestoSacubitril/Valsartan237$228,888
XareltoRivaroxaban127$139,222
JardianceEmpagliflozin134$102,344
Repatha SureclickEvolocumab51$47,290
FarxigaDapagliflozin Propanediol30$19,409
BrilintaTicagrelor25$13,040
Praluent PenAlirocumab13$8,492
Atorvastatin Calcium1,005$7,979
Metoprolol Succinate806$7,291
Carvedilol1,058$6,107
ClopidogrelClopidogrel Bisulfate576$4,802
VascepaIcosapent Ethyl13$4,313
Losartan Potassium678$4,124
Rosuvastatin Calcium395$3,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$750,151860 claims
Johnson & JohnsonXarelto$125$139,222127 claims
Boehringer IngelheimJardiance$72$102,344134 claims
AstraZenecaFarxiga, Brilinta$14$32,45055 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Miamisburg

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →